U.S. market Closed. Opens in 11 hours 16 minutes

VERV | Verve Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue11.76M1.94MN/AN/AN/A
Cost of Revenue5.46M6.71M3.38M1.33M106.00K
Gross Profit6.30M-4.77M-3.38M-1.33M-106.00K
Operating Expenses229.43M167.63M87.07M40.63M13.64M
Selling, General & Admin44.48M37.53M18.86M5.26M2.50M
Research & Development184.95M130.09M68.20M35.37M11.14M
Other Operating Expenses165.00K1.49M-33.39M-5.24M-5.93M
Operating Income-223.12M-165.69M-87.07M-40.63M-13.64M
Other Expenses / Income23.33M8.35M-33.25M-5.08M-5.66M
Before Tax Income-199.79M-157.33M-120.31M-45.70M-19.30M
Income Tax Expenses275.00K53.00K-1.68M-162.00K-278.00K
Net Income-200.07M-157.39M-118.64M-45.54M-19.02M
Interest ExpensesN/A-8.35MN/AN/AN/A
Basic Shares Outstanding64.18M54.02M48.51M48.22M48.22M
Diluted Shares Outstanding64.18M54.02M48.51M48.22M48.22M
EBITDA-217.67M-162.88M-87.07M-39.30M-13.54M
EBITDA Margin-1,851.24%-8,391.71%0.00%0.00%0.00%
EBIT-199.79M-165.69M-120.31M-45.70M-19.30M
EBIT Margin-1,699.21%-8,536.17%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙